May 4, 2026 03:11PM
May 1, 2026 03:15PM
May 1, 2026 01:56PM
May 1, 2026 09:36AM
May 1, 2026 08:38AM
Mar 30, 2026 08:05AM
Mar 16, 2026 05:40PM BofA maintains Underperform on Esperion Therapeutics (ESPR) despite favorable new AHA/ACC guidelines
Mar 16, 2026 06:31AM
Mar 13, 2026 05:40AM
Mar 10, 2026 12:17PM
Mar 10, 2026 06:52AM
Feb 17, 2026 08:00AM
Dec 22, 2025 07:06AM
Nov 25, 2025 12:48AM Piper Sandler Starts Esperion Therapeutics (ESPR) at Overweight
Nov 21, 2025 08:01AM
Nov 18, 2025 07:02AM
Nov 12, 2025 07:02AM
Nov 12, 2025 04:57AM
Nov 6, 2025 06:31AM
Oct 17, 2025 07:12AM
Oct 17, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
Oct 6, 2025 06:48AM
Oct 3, 2025 08:00AM
Sep 22, 2025 06:46AM
Sep 22, 2025 04:24AM
Sep 19, 2025 08:02AM
Aug 11, 2025 04:13PM
Aug 5, 2025 06:19AM Esperion Therapeutics (ESPR) Tops Q2 EPS by 12c
Jul 24, 2025 12:48PM
Jul 8, 2025 08:01AM
Jul 1, 2025 08:07AM
Jun 17, 2025 06:39AM
Jun 13, 2025 07:18AM
Jun 2, 2025 08:03AM
May 12, 2025 08:03AM Esperion Therapeutics (ESPR) Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL Prior to April 19, 2040
May 8, 2025 06:30AM
May 6, 2025 06:37AM
Apr 25, 2025 06:56AM
Apr 24, 2025 08:03AM
Apr 1, 2025 08:03AM
Mar 24, 2025 05:45AM
Mar 20, 2025 08:00AM Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid
Mar 5, 2025 05:28AM
Mar 4, 2025 06:09AM
Mar 3, 2025 08:01AM
Feb 11, 2025 06:45AM
Feb 11, 2025 04:13AM
Jan 23, 2025 07:07AM
Jan 16, 2025 10:28AM Esperion Therapeutics (ESPR): research & development expenses are expected to be in the range of $55 million to $65 million
Dec 18, 2024 07:01AM

401,101 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All